While the FDA-approved HDAC inhibitors produce prolonged responses in some patients, the overall response rate in CTCL and PTCL is relatively low (~30%), highlighting the need for more effective treatments40. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.